New Frontiers in Prostate Cancer Treatment: Are We Ready for Drug Combinations with Novel Agents?

New Frontiers in Prostate Cancer Treatment: Are We Ready for Drug Combinations with Novel Agents?

Medical treatment for metastatic castration-resistant prostate cancer (mCRPC) patients has progressively been evolving from a nonspecific clinical approach to genomics-oriented therapies. The scientific community is in fact increasingly focusing on developing DNA damage repair (DDR) defect-driven no...

Full description

Bibliographic Details
Main Authors: Gaetano Aurilio, Alessia Cimadamore, Matteo Santoni, Franco Nolè, Marina Scarpelli, Francesco Massari, Antonio Lopez-Beltran, Liang Cheng, Rodolfo Montironi
Format: Article
Language:English
Published: MDPI AG 2020-06-01
Series:Cells
Subjects:
prostate cancer
metastatic castration-resistant prostate cancer
DNA damage repair
ARS inhibitors
PARP inhibitors
immune checkpoint inhibitors
Online Access:https://www.mdpi.com/2073-4409/9/6/1522

Internet

https://www.mdpi.com/2073-4409/9/6/1522

Similar Items